An Imaging Agent (Fluorodopa F 18) with Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients with High-Grade Soft Tissue Sarcomas

Status: closed to accrual

This study evaluates the use of a new imaging agent called fluorodopa F 18 (18F-DOPA) with positron emission tomography/magnetic resonance imaging (PET/MRI) for assessing treatment response in patients undergoing standard of care radiation therapy and/or surgery for high-grade soft tissue sarcomas that are new or that have come back (recurrent). Though there have been improvements in treatment options for soft tissue sarcomas, there is currently a need for a non-invasive way to determine a patient's potential benefit from receiving one of these treatments. 18F-DOPA with PET/MRI allows a patient's tumor to be visualized and their response to a given treatment assessed.

Inclusion Criteria

PRE-ELIGIBILITY - INCLUSION CRITERIA:
Age >= 18 years
Histological confirmation of newly diagnosed soft tissue sarcoma, or recurrent soft tissue sarcoma >= 1-year post-treatment
Tumors > 1 cm in diameter in largest dimension located midline within the torso or neck, retroperitoneal, or lower extremities
Operable sarcoma, planning to receive surgery with or without neoadjuvant RT/chemotherapy at Mayo Clinic Florida. Systemic therapy is allowed during radiotherapy
Provide informed written consent
Willingness to participate in mandatory imaging studies at Mayo Clinic Florida

Exclusion Criteria

POST-ELIGIBILITY - EXCLUSION CRITERIA:
18F-DOPA PET uptake deemed as unacceptable for quantitative assessment
Unable to undergo an 18F-DOPA PET/MRI scan due to standard MRI restrictions, such as for those with certain implanted devices, those who cannot fit inside the bore, or those with severe claustrophobia
Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception

PRIMARY OBJECTIVE:

I. Determine the correlation between 18F-DOPA PET/MRI quantitative metrics after neoadjuvant treatment (pre-surgery) with percent tumor necrosis.

SECONDARY OBJECTIVE:

I. Compare the changes in 18F-DOPA PET/MRI quantitative metrics between baseline (before radiotherapy [RT]) and after RT, but before surgery with percent tumor necrosis.

OUTLINE:

Patients receive 18F-DOPA intravenously (IV) and undergo PET/MRI over 60 minutes before standard of care radiotherapy and/or before standard of care surgery.

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

An Imaging Agent (Fluorodopa F 18) with Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients with High-Grade Soft Tissue Sarcomas

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help